摘要
目的评价伊立替康（CPT-11）联合顺铂（DDP）方案一线治疗晚期非小细胞肺癌（NSCLC）的疗效和不良反应。方法经病理学或细胞学确诊的初治晚期NSCLC患者35例，男20例，女15例，年龄35～60岁，KPS评分〉70分。顺铂75mg／m^2第1～3天静脉输注，CPT-11100mg／m^2第1、8天静脉输注，每3周重复1次，至少2周期以上可评价疗效及不良反应。结果全组CR1例（2．8％），PR10例（28．6％），SD20例（57．1％），PD4例（11．4％）。整体客观有效率为31．4％（11／35），疾病控制率88．5％，中位治疗至进展时间为199d，1年生存率为54．3％（19／35），2年生存率为11．4％（4／35）。Ⅲ度和Ⅳ度不良反应的发生率为粒细胞减少17．1％，血小板减少2．8％，脱发17．1％，腹泻8．6％，恶心、呕吐2．8％。结论CPT-11联合DDP方案对晚期NSCLC治疗有效，患者耐受性良好。
Objective To evaluate the efficacy of irinotecan （ CPT - 11 ） combined with cisplatin （DDP） in the first - line treatment of advanced NSCLC and the adverse reactions. Methods 35 patients diagnosed as having advanced NSCLC by pathology or cytology were enrolled, including 20 men and 15 women. The median age was 47 years, KPS score 〉 70. DDP was given at 75mg/m^2 by intravenous infusion from day 1 to day 3, and CPT - 11 was given at 100 mg/m^2 by intravenous drip on day 1 and day 8, with the regimen given every 3 weeks for at least 2 cycles to assess the ef- ficacy and possible adverse reaction. Results Totally, t14 cycles were carried out in these 35 patients with a medium cycles of 3. Of the 35 evaluable patients, there was 1 case （2.8%） of complete response （ CR）, 10 cases （28.6%） of partial response （ PR）, 20 cases （57.1% ） of stable disease （SD） and 4 cases （ 11.4% ） of progressive disease （ PD）, with an objective response rate of 31.4% （11/35） and a disease control rate of 88.5%. The median survival time was 199 days, the actual 1 - year survival rate being 54.3% （ 19/35 ） and 2 - year survival rate being 11.4% （4/35）. The grade Ⅲ/Ⅳ adverse events included neutropenia （ 17.1% ）, thromboeytopenia （2.8%）, alopeeia （ 17.1% ）, diarrhea （8.6%）, nausea and vomiting （2.8%）. Conclusion CPT - 11 combined with DDP is effective in the treatment of advanced NSCLC with tolerable adverse events.
出处
《徐州医学院学报》
CAS
2010年第3期187-189,共3页
Acta Academiae Medicinae Xuzhou
关键词
伊立替康
顺铂
非小细胞肺癌
化学疗法
irinotecan
eisplatin
non- small cell lung cancer
chemotherapy
